Albert Wolkerstorfer

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Abstract There is an unmet need for repigmentation therapies for patients with nonsegmental vitiligo (NSV) who are candidates for systemic therapy. Here, 52-week primary results are reported from two parallel phase 3, randomized, double-blind, placebo-controlled trials of once-da...

Assessing the content validity of the 2015 core domain set for vitiligo clinical trials: preliminary investigations for developing an updated version

Abstract Background The 2015 core domain set (CDS) for vitiligo defines outcomes for clinical trials, comprising three essential and four recommended outcome domains/domain items. Periodic reassessment is required to ensure its continued relevance. Objectives To evaluate the cont...

The Safety of Melasma Treatment in Vitiligo Patients: An International E‐Delphi Study

ABSTRACT Vitiligo and melasma frequently coexist, creating a treatment dilemma, since agents effective for one condition can destabilize the other, and no consensus currently exists on safe management. We conducted a scoping literature review (through June 2023) on treatment of p...